S 2710

0likes☆Favorite🔕SubscribeShare

Introduced ↻ Update bill dataRe-checks Congress.gov for new actions and updates the bill's status, and fills in any sponsors, committees, or related bills that are missing. It does not re-pull sponsors/cosponsors/committees/related — those rarely change — and it skips all work if nothing has changed upstream, so it's cheap to click. Contact your reps Urge the sponsor

IN THE SENATE OF THE UNITED STATES

September 4, 2025

Mr. Grassley (for himself and Ms. Hassan) introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To amend title XI of the Social Security Act to require pharmaceutical and device manufacturers to publicly disclose covered payments made to patient advocacy organizations.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

This Act may be cited as the “Open Payments Expansion Act”.

SEC. 2. DISCLOSURE OF PHARMACEUTICAL AND DEVICE MANUFACTURER COVERED PAYMENTS TO PATIENT ADVOCACY ORGANIZATIONS.

(a) In General.—Section 1128G of the Social Security Act (42 U.S.C. 1320a-7h) is amended—

(1) in subsection (a), by adding at the end the following new paragraph:

“(3) Donations to patient advocacy organizations.—

“(A) In general.—In addition to the requirements under paragraphs (1) and (2), on March 31, 2027, and on the 90th day of each calendar year beginning thereafter, any applicable manufacturer or applicable group purchasing organization shall submit to the Secretary, in such electronic form as the Secretary shall require, details regarding any covered payment made by such manufacturer or organization to any patient advocacy organization, including—

“(i) the name of the patient advocacy organization; and

“(ii) the amount of the covered payment.

“(B) Definitions.—In this paragraph:

“(i) Covered payment.—The term ‘covered payment’ means any—

“(I) payment or other transfer of value; or

“(II) indirect payment or other transfer of value.

“(ii) Indirect payment or other transfer of value.—The term ‘indirect payment or other transfer of value’ means a payment or other transfer of value made by an applicable manufacturer or applicable group purchasing organization to a patient advocacy organization through a third party, where the applicable manufacturer or applicable group purchasing organization requires, instructs, directs, or otherwise causes the third party to provide the payment or transfer of value, in whole or in part, to a patient advocacy organization.

“(iii) Patient advocacy organization.—The term ‘patient advocacy organization’ means an organization described in section 501(c)(3) of the Internal Revenue Code of 1986 that is exempt from taxation under section 501(a) of such Code that—

“(I) provides education, advocacy, and support services oriented towards patients and caregivers;

“(II) is concerned with a medical condition diagnosed by a licensed medical practitioner who is in good standing with a State licensing body; or

“(III) has a mission that seeks to help vulnerable individuals affected by medical conditions or to help the families of such vulnerable individuals and takes actions consistent with such mission.”; and

(2) in subsection (c)(1)(C)(ix), by striking “or covered recipient” each place it appears and inserting “covered recipient, or patient advocacy organization”.

(b) Administration.—Chapter 35 of title 44, United States Code, shall not apply to this section or the amendments made by this section. <all>